Valneva Share: Among the Strongest Declines in the SBF 120, the Stock Falls 2.5%
The Lyon-based vaccine laboratory is losing ground in early afternoon, even as the SBF 120 is up slightly. The stock abandons a technical support level monitored over several sessions and extends a decline of several weeks. Already yesterday, it had lost another support level.
A Support of €2.61 Abandoned and Last Place in the Index
The price of Valneva is falling to €2.55 (-2.53% during the session), below the support of €2.61 that had contained selling pressure in recent days. The SBF 120 index is up 0.42% over the same period, so Valneva is among the strongest declines in the SBF 120 for the session. The stock broke through its support of €2.66 the previous day.
The stock is now below all three moving averages: the MA20 at €2.81 is 9.43% above the price, the MA50 at €2.65 is 3.96% above the price, and the MA200 at €3.08 is 17.37% above the price. The MACD remains negative and the histogram is widening from the signal line, a sign of selling momentum building. The decline is 4.75% over seven days and 9.3% over one month, while the stock retains +13.21% over three months.
2026 Guidance Confirmed Despite Persistent Impact of Geopolitical Context on Travel
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Upon publication of the first half of 2026 results on August 13, Valneva had confirmed its outlook for 2026, while noting that the geopolitical context continued to weigh on travel vaccine sales. The group also mentioned expected improvement in gross margins in the second half, following the impact of non-recurring items in the first half. Valneva is listed both in Paris (VLA, eligible for PEA) and on the Nasdaq in the form of ADS (VALN), with no material difference between the two lines: Paris concentrates the bulk of trading volumes. The €2.61 level now becomes a level to recapture on the upside, with the next resistance found at €2.99.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
